Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market
I'm PortAI, I can summarize articles.
The obesity drug market could shift from niche to mainstream by 2026, driven by oral GLP-1 pills from Novo Nordisk and Eli Lilly, and expanded government coverage. Novo's oral semaglutide may be approved soon, while Lilly's orforglipron targets a 2026 launch. Pills offer convenience and lower costs. A Medicare and Medicaid expansion could increase market reach. Analysts project a 30% market penetration, with potential revenue growth. Shareholders will watch approval timelines and market adoption closely.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: GuruFocus The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments